None
Quote | HOOKIPA Pharma Inc. (NYSE:HOOK)
Last: | $ |
---|---|
Change Percent: | -3.60% |
Open: | $12.50 |
Close: | $12.04 |
High: | $12.6839 |
Low: | $12.00 |
Volume: | 80,315 |
Last Trade Date Time: | 02/12/2020 04:41:40 pm |
News | HOOKIPA Pharma Inc. (NYSE:HOOK)
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from...
2024-04-24 14:01:40 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to cut 30% of workforce in wake of Roche deal termination Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical ...
Message Board Posts | HOOKIPA Pharma Inc. (NYSE:HOOK)
Subject | By | Source | When |
---|---|---|---|
$HOOK Price gaining | trendzone | investorshub | 05/08/2023 2:04:57 AM |
https://stockcharts.com/h-sc/ui?s=hook&p=D&yr=0&mn=6&dy=0&id=p38090673899 | surf1944 | investorshub | 05/06/2023 1:43:55 PM |
Price gaining last up | MADDSTACKER | investorshub | 05/06/2023 2:03:59 AM |
znewcar1: $HOOK f54.7M Hod 1.78 w/ 21% v2,509,109 @1.6500 f54,722,339 | znewcar1 | investorshangout | 05/05/2023 7:49:29 PM |
what does this mean? | trendzone | investorshub | 05/04/2023 12:32:05 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from...
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. ...